VJHemOnc Podcast

Patients with cancer frequently exhibit poorer post-COVID-19 infection outcomes, therefore the management of patients with hematological malignancies remains of high importance. Several strategies have been employed to reduce the risk of infection, whilst still providing appropriate therapies for high-risk patients.

In this podcast, Paul Richardson, of the Dana-Farber Cancer Institute, Boston, MA, chairs a thoughtful discussion with María-Victoria Mateos of the University Hospital of Salamanca, Salamanca, Spain, Evangelos Terpos of the University of Athens, Athens, Greece, and Ajai Chari of Mount Sinai, New York, NY, on the treatment of multiple myeloma in the face of the COVID-19 pandemic. The speakers discuss evolving strategies to reduce risk of COVID-19 infection in myeloma patients, perspectives from Spain, New York, and Greece, recommendations from the International Myeloma Society (IMS), as well as the key updates following the virtual ASCO and EHA meetings.

The post The Myeloma Sessions: Evolving management of myeloma & COVID-19 appeared first on VJHemOnc.

It is an exciting time in terms of therapeutic progress for myeloproliferative neoplasms (MPN). In recent years, there have been significant advances in the understanding of MPNs, including underlying genetic changes that drive the development of MPNs. This has led to research focusing on targeted therapy and increased the availability of new treatment options.

The post MPNs highlights at EHA 2020: clinical trials, novel therapies & pitfalls appeared first on VJHemOnc.

A remarkable increase in the understanding of the pathogenesis of chronic lymphocytic leukemia (CLL) has led to the development of innovative therapies which has generated rapid progress in the management of CLL.

In this podcast, John Gribben of Barts Cancer Institute, London, UK, chairs an insightful discussion with Barbara Eichhorst of the University of Cologne, Cologne, Germany, Susan O’Brien of the University of California, Irvine, CA, and Matthew Davids of Dana-Farber Cancer Institute, Boston, MA, on the latest CLL updates from the recent Virtual ASCO and EHA 2020 Meetings. The speakers discuss frontline therapy for CLL, BTK inhibitors, novel combination therapies and the importance of measurable residual disease (MRD) assessment. Treatment sequencing and novel therapies, in particular CAR T-cell approaches were also discussed.

The post The CLL Sessions: frontline therapy, BTK inhibitors, MRD negativity & novel therapies appeared first on VJHemOnc.

The ongoing COVID-19 pandemic caused by SARS-CoV-2 is an international public health issue and patients with cancer consistently demonstrate poorer post-infection outcomes. In this podcast, Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, chairs an exciting discussion with Jan Philipp Bewersdorf, Yale University and Yale Cancer Center, New Haven, CT, Rory Shallis, MD, Yale University and Yale Cancer Center, New Haven, CT, and John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY. These speakers discuss their recent collaborative publication in Lancet Hematology, evaluating the management of adult patients with acute leukemias and myeloid neoplasms in the COVID-19 era.

The post The HemOnc & COVID-19 Sessions: treating hematological malignancies, reducing nosocomial COVID-19 infections, clinical trial participation and resource allocation appeared first on VJHemOnc.

The acute myeloid leukemia (AML) field has witnessed rapid evolution of late, with exciting developments in strategies for the treatment of the disease. 

In this podcast, Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX,  chairs a discussion with Marion Subklewe, MD, LMU Hospital Munich, Munich, Germany, Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, and Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia. The spreakers debate the key updates in the treatment of AML from the recent ASCO and EHA 2020 virtual meetings including emerging immunotherapies, venetoclax-based regimens and targeted therapies in AML.

The post The AML Sessions: emerging immunotherapies, venetoclax-based regimens and targeted therapies in AML appeared first on VJHemOnc.